- Home
- AMWD vs EVMN Comparison
AMWD vs EVMN Comparison
Compare AMWD & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMWD | EVMN |
|---|---|---|
| Founded | 1980 | 2020 |
| Country | United States | United States |
| Employees | N/A | 48 |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 566.8M | 825.5M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | AMWD | EVMN |
|---|---|---|
| Price | $48.09 | $23.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $59.50 | $43.88 |
| AVG Volume (30 Days) | 355.2K | ★ 381.8K |
| Earning Date | 05-28-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,709,585,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.29 | $13.89 |
| 52 Week High | $72.16 | $33.20 |
Technical Indicators
Market Signals| Indicator | AMWD | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 69.39 | 46.84 |
| Support Level | $47.15 | $21.32 |
| Resistance Level | $58.38 | $23.08 |
| Average True Range (ATR) | 2.26 | 1.25 |
| MACD | 1.08 | 0.13 |
| Stochastic Oscillator | 98.44 | 51.43 |
Price Performance
Historical ComparisonAbout AMWD American Woodmark Corporation
American Woodmark Corp manufactures and distributes cabinets and vanities for the remodeling and new home construction markets. It offers several products that fall into product lines including kitchen cabinetry, bath cabinetry, office cabinetry, home organization, and hardware. The products are sold under the brand names American Woodmark, Timberlake, Shenandoah Cabinetry, and Waypoint Living Spaces among others.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.